Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 3/20 | 0.41 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.37 |
| ▸ | PLK1 | P53350 | 1/20 | 0.37 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.37 |
| ▸ | PLK3 | Q9H4B4 | 1/20 | 0.37 |
| ▸ | PLK2 | Q9NYY3 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502077 | 0.87 | MAPT (0.54) | ALDH1A1MAPTLMNAHTTDAPK3 | |
| SCHEMBL10414626 | 0.87 | MAPT (0.54) | ALDH1A1MAPTLMNAHTTSMN1; SMN2 | |
| SCHEMBL9121830 | 0.83 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNAHTTMEN1 | |
| SCHEMBL321260 | 0.81 | MAPT (0.44) | ALDH1A1MAPTMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL14395833 | 0.81 | CCNA2 (0.44) | ALDH1A1MAPTHTTMEN1KMT2A | |
| SCHEMBL9125254 | 0.80 | ALDH1A1 (0.51) | ALDH1A1MAPTLMNAHTTDAPK3 | |
| SCHEMBL3668058 | 0.78 | ALDH1A1 (0.45) | ALDH1A1MAPTLMNAHTTDAPK3 | |
| SCHEMBL14086979 | 0.78 | MAPT (0.42) | ALDH1A1MAPTLMNAHTTMEN1 | |
| SCHEMBL9124439 | 0.77 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAHTTDAPK3 | |
| SCHEMBL9124111 | 0.77 | ALDH1A1 (0.44) | ALDH1A1MAPTLMNAHTTDAPK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12415811-B2 | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-C]pyrrole]-2,3'-dione compounds as therapeutic agents activating TP53 | ADAMED PHARMA S.A. (PL) | 2025-09-16 | — | — | US | disclosed |
| CN-111566110-B | 1,2,3',5' -tetrahydro-2 ' H-spiro [ indole-3, 1' -pyrrolo [3,4-C ] pyrrole ] -2,3' -dione compounds as therapeutic agents for activating TP53 | 阿达梅德制药公司 | 2023-04-25 | — | — | CN | disclosed |
| EP-3740492-B1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S A (PL) | 2022-03-02 | — | — | EP | disclosed |
| EP-3740492-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | Adamed Pharma S.A. (PL) | 2020-11-25 | — | — | EP | disclosed |
| US-20200354372-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA, S.A. (PL) | 2020-11-12 | — | — | US | disclosed |
| US-20200354372-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA, S.A. (PL) | 2020-11-12 | — | — | US | disclosed |
| CN-111566110-A | 1,2,3',5' -tetrahydro-2 ' H-spiro [ indole-3, 1' -pyrrolo [3,4-C ] pyrrole ] -2,3' -dione compounds as therapeutic agents for activating TP53 | 阿达梅德制药公司 | 2020-08-21 | — | — | CN | disclosed |
| WO-2019141549-A9 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S.A. (PL) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019141549-A9 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S.A. (PL) | 2019-10-10 | — | — | WO | disclosed |
| WO-2019141549-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | ADAMED PHARMA S.A. (PL) | 2019-07-25 | — | — | WO | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| US-7407649-B2 | Compounds having a benzene ring substituted with 1 or 2 trialkylsilyl(alkyl) groups and at least 2 additional aryl or heteroaryl rings: 5-[2-methyl-5-(trimethylsilyl)phenoxy]-N-(2,6-dimethoxyphenyl)furan-2-carboxamide; Gonadotropin-Releasing Hormone antagonists; anticancer agents | PARADIGM THERAPEUTICS LTD (GB) | 2008-08-05 | — | — | US | disclosed |
| EP-1648906-B1 | ORGANOSILICON COMPOUNDS AND THEIR USE | TAKEDA CAMBRIDGE LTD (GB) | 2007-10-03 | — | — | EP | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070110708-A1 | Silicon compounds and their use | PARADIGM THERAPEUTICS LTD (GB) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| US-20070111967-A1 | Organosilicon compounds and their use | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-05-17 | — | — | US | disclosed |
| EP-1401427-A4 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | AGOURON PHARMA (US) | 2004-12-01 | — | — | EP | disclosed |
| EP-1401427-A2 | NON-PEPTIDE GNRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | Agouron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002098363-A2 | NON-PEPTIDE GnRH AGENTS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USES, AND PROCESSES FOR PREPARING THEM | AGOURON PHARMACEUTICALS, INC. (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070110708-A1 | Silicon compounds and their use | SOST, SMAD3, SMAD2 | ALDH1A1 2166/4885MAPT 916/4885LMNA 1870/4885 |
| US-12415811-B2 | 1,2,3',5'-tetrahydro-2'h-spiro[indole-3,1'-pyrrolo[3,4-C]pyrrole]-2,3'-dione compounds as therapeutic agents activating TP53 | TP53, IDO1, TP53BP1 | ALDH1A1 337/4885MAPT 2133/4885LMNA 3114/4885 |
| US-20070111967-A1 | Organosilicon compounds and their use | CYP2B6, UGT1A6, CYP2D6 | ALDH1A1 198/4885MAPT 2134/4885LMNA 2597/4885 |
| US-20200354372-A1 | 1,2,3',5'-TETRAHYDRO-2'H-SPIRO[INDOLE-3,1'-PYRROLO[3,4-C]PYRROLE]-2,3'-DIONE COMPOUNDS AS THERAPEUTIC AGENTS ACTIVATING TP53 | TP53, IDO1, TP53BP1 | ALDH1A1 337/4885MAPT 2133/4885LMNA 3114/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.